Abbott Laboratories fell 17.4% from $130.03 to $107.45, behind the S&P 500's +11.2%. Its worst day was Jan 22 (−10.0%), and its low came May 11 at $82.56.
Story events cover the past 12 months · Times ET
Nov 17, 2025 – Nov 16, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $1.50 beat the $1.50 estimate on $11.5B revenue (est. $11.8B); Q1 EPS guidance of $1.12–$1.18 against the $1.20 consensus.
−10.0%, the year's worst day · S&P 500 +0.5%
EPS of $1.15 beat the $1.14 estimate on $11.2B revenue (est. $11.0B); FY EPS guidance of $5.38–$5.58 against the $5.55 consensus.
−6.0% · S&P 500 +0.2%
Abbott Laboratories closed at its lowest level of the year, 36.5% below where the year started.
−2.1% · S&P 500 +0.2%
EPS of $1.31 beat the $1.28 estimate on $12.6B revenue (est. $12.5B); Q3 EPS guidance of $1.38–$1.46 against the $1.42 consensus.
+10.7%, the year's best day · S&P 500 −0.5%
EPS of $1.42 beat the $1.42 estimate on $13.0B revenue (est. $13.0B); Q4 EPS guidance of $1.62–$1.67 against the $1.64 consensus.
−1.9% · S&P 500 +0.5%
Abbott Laboratories shares rose 5.6%, while the S&P 500 rose 1.7%.
+5.6% · S&P 500 +1.7%
Where it ended: a close of $107.45 on Nov 16, 2026. Up next: Q4 2026 earnings on Jan 21, 2027 (EPS est. $1.64, revenue est. $13.2B).
